Heart valve infection study questions standard antibiotic
NCT ID NCT07253688
Summary
This study aims to find out if doctors can safely skip the antibiotic rifampin when treating serious Staph infections on artificial heart valves. It will compare outcomes for 330 patients who either receive or do not receive rifampin alongside standard treatment. The goal is to see if avoiding this drug, which can cause side effects and interact with other medications, is just as effective for controlling the infection.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAPHYLOCOCCUS AUREUS ENDOCARDITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)
RECRUITINGMontreal, Quebec, H4A4S1, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.